Personalized medicine: individualized care of cancer patients.

[1]  D. Bergsagel.  Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? , 1989, European journal of cancer & clinical oncology.

[2]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[3]  M. Ng,et al.  Frequent hypermethylation of p16 and p15 genes in multiple myeloma. , 1997, Blood.

[4]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[5]  R. Papac.  Origins of cancer therapy. , 2001, The Yale journal of biology and medicine.

[6]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[7]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[8]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[9]  Leroy Hood,et al.  Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. , 2004, Journal of proteome research.

[10]  David M. Goldenberg,et al.  CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy , 2004, Clinical Cancer Research.

[11]  S. Ely,et al.  Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. , 2005, Cancer research.

[12]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[13]  S. Ely,et al.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.

[14]  A. Whittemore,et al.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men , 2006, Proceedings of the National Academy of Sciences.

[15]  Irene L Andrulis,et al.  HER2 and responsiveness of breast cancer to adjuvant chemotherapy. , 2006, The New England journal of medicine.

[16]  Ugo Pastorino,et al.  Computed tomography screening and lung cancer outcomes. , 2007, JAMA.

[17]  I. Thompson,et al.  Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. , 2007, International journal of epidemiology.

[18]  A. Pettitt,et al.  The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.

[19]  Yixiang Wang,et al.  Immunotherapy of melanoma: a critical review of current concepts and future strategies , 2007, Expert opinion on biological therapy.

[20]  R. Prescott,et al.  Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[22]  D. Goldstein.  Common genetic variation and human traits. , 2009, The New England journal of medicine.

[23]  P. Kantoff,et al.  Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality , 2009, Clinical Cancer Research.

[24]  I. Andrulis,et al.  Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. , 2009, Journal of the National Cancer Institute.